Dose Escalation of IPI-493 in Hematologic Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2010 |
| End Date: | October 2011 |
A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies With Client Proteins of Hsp90
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose
(MTD) and schedule of IPI-493 in patients with hematologic malignancies.
We found this trial at
3
sites
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
Click here to add this to my saved trials